Prevention of infection and bleeding in leukemic patients receiving intensive remission maintenance therapy.
Prevention of infection and bleeding in leukemic patients receiving intensive remission maintenance therapy.
复制标题
预防接受强化缓解维持治疗的白血病患者的感染和出血。
DOI：
10.1002/mpo.2950090515
复制
发表时间：
1981
期刊：
影响因子：
--
通讯作者：
Hryniuk,W
中科院分区：
文献类型：
--
作者：
Preisler,HD;Early,A;Hryniuk,W
白血病患者接受强化化疗，以减少诱导完全缓解后剩余的白血病细胞数量。这种治疗导致严重的粒细胞减少和血小板减少。考虑到13例未接受抗菌预防治疗的患者，记录的感染相当普遍，包括4次菌血症和3次尿路感染。相比之下，服用复方新诺明作为抗菌预防药物的患者发热发作次数减少了一半，没有出现严重感染。在本研究中，预防性复方新诺明对骨髓缓解患者有益。白血病骨髓患者的类似获益仍有待证实。当血小板计数< 2万/μl时，患者均接受预防性血小板输注，每周3次。除了瘀点外，没有出血发作。
Leukemic patients were treated with intensive chemotherapy to reduce the number of leukemic cells remaining after complete remission was induced. This therapy resulted in periods of severe granulocytopenia and thrombocytopenia. Considering 13 patients who did not receive antibacterial prophylaxis, documented infection was quite common including four episodes of bacteremia and three urinary tract infections. By contrast, patients who received co‐trimoxazole as antibacterial prophylaxis experienced one half as many febrile episodes and no serious infections. Prophylactic co‐trimoxazole is beneficial for patients with marrow remission in this study. Similar benefit in patients with leukemic marrows remains to be established. All patients received prophylactic platelet transfusions three times a week when their platelet counts were < 20,000/μl. There were no episodes of bleeding other than petechiae.